Vanda Pharmaceuticals targets $1B revenue by 2030 with expanded psychiatry portfolio
Vanda Pharmaceuticals sees strong growth with Fanapt for bipolar I disorder, projects 2025 revenue up 6%-26%, and targets $1B by 2030.
Saudi Gazette on MSN4d
Sanofi is transferring its global expertise in insulin production to Saudi Arabia, aligning with Vision 2030 program
As Saudi Arabia moves toward healthcare self-sufficiency under Vision 2030, the localization of vital pharmaceutical manufacturing has become a critical priority. In a major step forward, Sanofi, ...